Peer Review reports
From: A new indolocarbazole derivative in melanoma and carcinoma lung in vivo treatment
| Original Submission | ||
|---|---|---|
| 11 Feb 2021 | Submitted | Original manuscript |
| Resubmission - Version 2 | ||
| Submitted | Manuscript version 2 | |
| Resubmission - Version 3 | ||
| Submitted | Manuscript version 3 | |
| 21 Feb 2021 | Reviewed | Reviewer Report |
| 2 Mar 2021 | Reviewed | Reviewer Report |
| 24 Mar 2021 | Author responded | Author comments - Lyudmila Nikolaeva |
| Resubmission - Version 4 | ||
| 24 Mar 2021 | Submitted | Manuscript version 4 |
| 24 Mar 2021 | Author responded | Author comments - Lyudmila Nikolaeva |
| Resubmission - Version 5 | ||
| 24 Mar 2021 | Submitted | Manuscript version 5 |
| 25 Mar 2021 | Reviewed | Reviewer Report |
| 30 Mar 2021 | Reviewed | Reviewer Report |
| Resubmission - Version 6 | ||
| Submitted | Manuscript version 6 | |
| Publishing | ||
| 31 Mar 2021 | Editorially accepted | |
| 10 Apr 2021 | Article published | 10.1186/s12906-021-03294-2 |
You can find further information about peer review here.